Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.
Quintarelli C, Sivori S, Caruso S, Carlomagno S, Falco M, Boffa I, Orlando D, Guercio M, Abbaszadeh Z, Sinibaldi M, Di Cecca S, Camera A, Cembrola B, Pitisci A, Andreani M, Vinti L, Gattari S, Del Bufalo F, Algeri M, Li Pira G, Moseley A, De Angelis B, Moretta L, Locatelli F. Quintarelli C, et al. Among authors: boffa i. Leukemia. 2020 Apr;34(4):1102-1115. doi: 10.1038/s41375-019-0613-7. Epub 2019 Nov 19. Leukemia. 2020. PMID: 31745215
Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.
Orlando D, Miele E, De Angelis B, Guercio M, Boffa I, Sinibaldi M, Po A, Caruana I, Abballe L, Carai A, Caruso S, Camera A, Moseley A, Hagedoorn RS, Heemskerk MHM, Giangaspero F, Mastronuzzi A, Ferretti E, Locatelli F, Quintarelli C. Orlando D, et al. Among authors: boffa i. Cancer Res. 2018 Jun 15;78(12):3337-3349. doi: 10.1158/0008-5472.CAN-17-3140. Epub 2018 Apr 3. Cancer Res. 2018. PMID: 29615432
Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts.
Quintarelli C, Guercio M, Manni S, Boffa I, Sinibaldi M, Di Cecca S, Caruso S, Abbaszadeh Z, Camera A, Cembrola B, Ciccone R, Orfao A, Martin-Martin L, Gutierrez-Herrero S, Herrero-Garcia M, Cazzaniga G, Nunes V, Songia S, Marcatili P, Marin FI, Ruella M, Bertaina V, Vinti L, Del Bufalo F, Algeri M, Merli P, De Angelis B, Locatelli F. Quintarelli C, et al. Among authors: boffa i. J Immunother Cancer. 2021 Jun;9(6):e001514. doi: 10.1136/jitc-2020-001514. J Immunother Cancer. 2021. PMID: 34135100 Free PMC article.
Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies.
Guercio M, Manni S, Boffa I, Caruso S, Di Cecca S, Sinibaldi M, Abbaszadeh Z, Camera A, Ciccone R, Polito VA, Ferrandino F, Reddel S, Catanoso ML, Bocceri E, Del Bufalo F, Algeri M, De Angelis B, Quintarelli C, Locatelli F. Guercio M, et al. Among authors: boffa i. Front Immunol. 2021 Oct 19;12:755639. doi: 10.3389/fimmu.2021.755639. eCollection 2021. Front Immunol. 2021. PMID: 34737753 Free PMC article.
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
Guercio M, Orlando D, Di Cecca S, Sinibaldi M, Boffa I, Caruso S, Abbaszadeh Z, Camera A, Cembrola B, Bovetti K, Manni S, Caruana I, Ciccone R, Del Bufalo F, Merli P, Vinti L, Girardi K, Ruggeri A, De Stefanis C, Pezzullo M, Giorda E, Scarsella M, De Vito R, Barresi S, Ciolfi A, Tartaglia M, Moretta L, Locatelli F, Quintarelli C, De Angelis B. Guercio M, et al. Among authors: boffa i. Haematologica. 2021 Apr 1;106(4):987-999. doi: 10.3324/haematol.2019.231183. Haematologica. 2021. PMID: 32381575 Free PMC article.
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.
Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, Giorda E, Scarsella M, Petrini S, Pagliara D, Locatelli F, De Angelis B, Caruana I. Quintarelli C, et al. Among authors: boffa i. Oncoimmunology. 2018 Mar 15;7(6):e1433518. doi: 10.1080/2162402X.2018.1433518. eCollection 2018. Oncoimmunology. 2018. PMID: 29872565 Free PMC article.
Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-β-OTX2-SNAIL via PTEN inhibition.
Ferrucci V, de Antonellis P, Pennino FP, Asadzadeh F, Virgilio A, Montanaro D, Galeone A, Boffa I, Pisano I, Scognamiglio I, Navas L, Diana D, Pedone E, Gargiulo S, Gramanzini M, Brunetti A, Danielson L, Carotenuto M, Liguori L, Verrico A, Quaglietta L, Errico ME, Del Monaco V, D'Argenio V, Tirone F, Mastronuzzi A, Donofrio V, Giangaspero F, Picard D, Remke M, Garzia L, Daniels C, Delattre O, Swartling FJ, Weiss WA, Salvatore F, Fattorusso R, Chesler L, Taylor MD, Cinalli G, Zollo M. Ferrucci V, et al. Among authors: boffa i. Brain. 2018 May 1;141(5):1300-1319. doi: 10.1093/brain/awy039. Brain. 2018. PMID: 29490009
A therapeutic approach to treat prostate cancer by targeting Nm23-H1/h-Prune interaction.
Carotenuto M, de Antonellis P, Chiarolla CM, Attanasio C, Damiani V, Boffa I, Aiese N, Pedone E, Accordi B, Basso G, Navas L, Imbimbo C, Zollo M. Carotenuto M, et al. Among authors: boffa i. Naunyn Schmiedebergs Arch Pharmacol. 2015 Feb;388(2):257-69. doi: 10.1007/s00210-014-1035-8. Epub 2014 Aug 20. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 25138575
Early targets of miR-34a in neuroblastoma.
De Antonellis P, Carotenuto M, Vandenbussche J, De Vita G, Ferrucci V, Medaglia C, Boffa I, Galiero A, Di Somma S, Magliulo D, Aiese N, Alonzi A, Spano D, Liguori L, Chiarolla C, Verrico A, Schulte JH, Mestdagh P, Vandesompele J, Gevaert K, Zollo M. De Antonellis P, et al. Among authors: boffa i. Mol Cell Proteomics. 2014 Aug;13(8):2114-31. doi: 10.1074/mcp.M113.035808. Epub 2014 Jun 9. Mol Cell Proteomics. 2014. PMID: 24912852 Free PMC article.
Natural compounds for pediatric cancer treatment.
Ferrucci V, Boffa I, De Masi G, Zollo M. Ferrucci V, et al. Among authors: boffa i. Naunyn Schmiedebergs Arch Pharmacol. 2016 Feb;389(2):131-49. doi: 10.1007/s00210-015-1191-5. Epub 2015 Dec 9. Naunyn Schmiedebergs Arch Pharmacol. 2016. PMID: 26650503 Review.
14 results